Supporting lentiviral vector development for cell therapies
Lentivirus is an efficient tool for fast, efficient, and cost-effective generation of stable homogeneous cell models for strong gene expression or gene knockdown. In gene therapy, Lentiviruses are widely used for CAR-T cell therapy applications.
Revvity gene delivery key advantages
De-risking: All our projects profit from more than 12 years in-house expertise in lentivirus vector technology.
Integrated development: We carefully consider the deep connection between the lead vector design and any challenge encountered during the development of a cell and gene therapy, including quality, potency and cost effectiveness.
Needs and technology focus: Our specialists are trained to support cell therapy developers by carefully discussing and identifying our clients’ needs. Project feasibility as well as a portfolio of development and manufacturing options are addressed in a sophisticated project set-up.
Revvity gene delivery key advantages
- De-risking
- Integrated development
- Needs and technology focus
For Research Use Only.
Lentiviral vectors for cell and gene therapy
Revvity Gene Delivery (formerly SIRION Biotech) provides a 360° end-to-end solution within the R&D and preclinical lentivirus space to develop safe and efficacious lentivirus-based drug products.
We offer capabilities and technologies to develop the key components of a lentivirus-based drug product:
- Therapeutic expression cassette development
- Lentiviral surface modification
- Manufacturing process tools and development
- Patented transduction enhancer technology LentiBOOST
Lentiviral vector manufacturing
Manufacturing of lentiviral particles for research follows our ISO certified manufacturing procedure.
Our experienced process development team also establishes advanced manufacturing procedures on demand for individual requirements for experimental validation and the experimental workflow.
GMP alliances
Our preclinical manufacturing processes – including custom developed advanced manufacturing procedures – are transferrable to partners within our closely aligned, worldwide CDMO network for GMP-manufacturing. This significantly speeds up the transfer process. We can additionally transfer the plasmid sequences for LV drug substance manufacturing and provide physical plasmid starting material via plasmid CDMO partners.
Questions?
We’re here to help.
Contact us Please note that product labeling (such as kit insert, product label, and kit box) may be different compared to the company branding. Please contact your local representative for further details.